Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
6
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
6
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
6
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
indiana blog main
indiana top stories
clinical trials
vertex pharmaceuticals
crispr-cas9
deals
glaxosmithkline
investing
merck
startups
amgen
bristol-myers squibb
What
roundup
bio
cancer
ahead
annual
asco
clinical
crispr
days
drug
fda
medicine
meeting
oncology
society
time
alliance
ambien
american
approved
ash
attendees
attention
barcelona
big
biotech
bosley's
bosley’s
branded
bridge
bristol
bucks
buy
calls
camp’s
cas
cash
ceo
changing
chicago
Language
unset
Current search:
roche
×
fda
×
" seattle top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
